34 results
8-K
EX-3.3
KA
Kineta, Inc.
22 Dec 22
Kineta Completes Reverse Merger with Yumanity Therapeutics
5:02pm
qualifies as an “independent director” or “audit committee financial expert” under applicable law, securities exchange rule or regulation and (ii … to such Proceeding;
(d) “Expenses” means all attorneys’ fees, retainers, court costs, transcript costs, fees of expert witnesses, private investigators
8-K
EX-10.7
1qzugukfo1y99cyw2c
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
EX-10.2
4cblum0 kk
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
EX-10.1
i3jmy 6m5d3xoavrt
30 Dec 20
Yumanity Therapeutics Completes Reverse Merger with Proteostasis Therapeutics
4:44pm
8-K
omfn su2rlznjdati
9 Dec 20
Other Events
5:27pm
425
y68svp qpdx9cd
9 Dec 20
Business combination disclosure
5:25pm
424B3
gs8et3quwrq6r2
12 Nov 20
Prospectus supplement
6:08am